Emcure Pharmaceuticals Reports 24% Revenue Growth and 29% Rise in PAT in Q2 FY27

manufacturing-news
SATISH MEHTA, CEO & MD, EMCURE PHARMA

Emcure Pharmaceuticals Limited (BSE: 544210, NSE: EMCURE) has reported a strong financial performance for the second quarter ended September 30, 2026, with consolidated revenue from operations increasing 24.3% year-on-year to ₹28,205 million. Profitability also improved, supported by broad-based growth across domestic and international markets, productivity gains and operating leverage.

EBITDA for the quarter rose 30.9% to ₹5,748 million, with the EBITDA margin expanding by 103 basis points to 20.4%. Profit After Tax (PAT) increased 29.3% to ₹3,251 million, while the PAT margin improved by 45 basis points to 11.5%. For the first half of FY27, revenue from operations grew 23.6% to ₹54,009 million. EBITDA stood at ₹5,748 million for the second quarter, while the company continued to invest in research and development, with expenditure of ₹1,110 million during the quarter, representing approximately 4% of revenue. Net debt stood at ₹13,171 million as of September 30, 2026.

Commenting on the performance, Satish Mehta, Chairman, Managing Director and CEO of Emcure Pharmaceuticals, said, “Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings. Revenue grew 24% year-on-year to ₹28,205 million, with India growing 12% and International 34.5%. EBITDA grew 31% to ₹5,748 million, with margin at 20.4%, an expansion of about 100 basis points, driven by productivity gains and operating leverage. PAT grew 29% to ₹3,251 million. We expect business momentum to sustain into H2 FY27.”

The domestic business recorded revenue of ₹11,553 million, registering 12% growth and contributing 41% to consolidated revenue. Performance was led by the Women’s Health franchise, Cardio-Metabolics and the CNS range, supported by improved traction in Poviztra. Zuventus also improved sequentially, while consumer health brands Bitter Drops and Galact gained traction. Domestic revenue for H1 FY27 reached ₹22,506 million, up 11.1%.

International revenue increased 34.5% to ₹16,652 million, accounting for 59% of consolidated revenue. Europe grew 36% to ₹6,043 million, supported by strong performance in the UK and continental Europe and the continued scale-up of Liposomal Amphotericin B. Canada recorded 24% growth to ₹4,312 million, while the Rest of World business grew 41.1% to ₹6,297 million, led by the ARV business and stronger non-ARV growth. International revenue for H1 FY27 stood at ₹31,503 million, up 34.5%.

During the quarter, Emcure received more than 20 product approvals across developed and emerging markets. Lenacapavir injection for the PrEP indication received a positive recommendation from India’s Subject Expert Committee, while Liposomal Amphotericin B was approved in Brazil and Mexico. Bevacizumab also received approval in India for wet age-related macular degeneration. The company filed the Lenacapavir injection dossier with the WHO and US FDA.

Separately, the Board approved a draft Composite Scheme of Amalgamation involving wholly owned subsidiaries Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, with Emcure Pharmaceuticals Limited. The proposed consolidation is intended to simplify the group structure and improve operational efficiency, subject to statutory and regulatory approvals, including approval from the National Company Law Tribunal, Mumbai Bench. Following the company’s Annual General Meeting on September 21, 2026, Satish Mehta assumed the role of Chairman of the Board in addition to his responsibilities as Managing Director and CEO.